報價延遲最少15分鐘:2025/02/23 08:32 EST
|
|
|
|
|
||||||||||||
|
|
|
|
|
7.46 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
0.27/1.21
|
|
企業價值
446.10M
|
| 資產負債 |
|
每股賬面淨值
4.44
|
| 現金流量 |
|
現金流量率
0.09
|
| 損益表 |
|
收益
142.52M
|
|
每股收益
2.54
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/02/23 08:32 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics. |